68Ga-PSMA-PET screening and transponder-guided salvage radiotherapy to the prostate bed alone for biochemical recurrence following prostatectomy: interim outcomes of a phase II trial - Summary - MDSpire

68Ga-PSMA-PET screening and transponder-guided salvage radiotherapy to the prostate bed alone for biochemical recurrence following prostatectomy: interim outcomes of a phase II trial

  • By

  • Patrick Bowden

  • Andrew W. See

  • Kevin So

  • Nathan Lawrentschuk

  • Daniel Moon

  • Declan G. Murphy

  • Ranjit Rao

  • Alan Crosthwaite

  • Dennis King

  • Hodo Haxhimolla

  • Jeremy Grummet

  • Paul Ruljancich

  • Dennis Gyomber

  • Adam Landau

  • Nicholas Campbell

  • Mark Frydenberg

  • Lloyd M. L. Smyth

  • Skye Nolan

  • Stella M. Gwini

  • Dean P. McKenzie

  • June 2, 2021

  • 0 min

Share

Objective:

To evaluate clinical outcomes over 10 years for patients receiving transponder-guided salvage radiotherapy (SRT) to the prostate bed alone, based on 68Ga-PSMA-PET results, starting from the time of treatment.

Key Findings:
  • 68Ga-PSMA-PET improved imaging accuracy and changed treatment strategy in up to two-thirds of patients, potentially leading to better outcomes.
  • Transponder-guided SRT aimed to minimize rectal toxicity and ensure accurate targeting of the prostate bed.
  • Interim results indicated promising rates of freedom from biochemical relapse.
Interpretation:

The use of 68Ga-PSMA-PET and transponder-guided SRT may enhance treatment outcomes for patients with biochemical recurrence post-prostatectomy, potentially reducing the risk of overtreatment.

Limitations:
  • Single-centre study may limit generalizability.
  • Interim results may not reflect long-term outcomes.
  • Lack of long-term follow-up data.
Conclusion:

Transponder-guided SRT based on 68Ga-PSMA-PET results shows potential for effective management of biochemical recurrence in prostate cancer, warranting further investigation to validate these findings in broader clinical practice.

Original Source(s)

68Ga-PSMA-PET screening and transponder-guided salvage radiotherapy to the prostate bed alone for biochemical recurrence following prostatectomy: interim outcomes of a phase II trial

  • by Patrick Bowden, Andrew W. See, Kevin So, Nathan Lawrentschuk, Daniel Moon, Declan G. Murphy, Ranjit Rao, Alan Crosthwaite, Dennis King, Hodo Haxhimolla, Jeremy Grummet, Paul Ruljancich, Dennis Gyomber, Adam Landau, Nicholas Campbell, Mark Frydenberg, Lloyd M. L. Smyth, Skye Nolan, Stella M. Gwini, Dean P. McKenzie

  • June 2, 2021

Related Content

Optimizing Outcomes: How Multidisciplinary Approaches Improve Prostate Cancer Survival Rates

Prostate cancer management has evolved significantly over the years, propelled by groundbreaking diagnostics and advancements in treatment modalities.

  • by

  • March 18, 2024

  • 4 min
Magnetic resonance imaging (MRI) for local staging before salvage radical prostatectomy: a meta-analysis

Adaptive Radiation Therapy Increases Safety and Preserves Quality of Life, Says Study

For patients with recurrent retroperitoneal sarcomas that cannot be treated surgically, treatment choices are limited. These tumors can grow quite large in the abdomen adjacent to vital organs or enmeshed within the bowel.

  • by

  • September 29, 2025

  • 4 min